Maggini Marina, Raschetti Roberto, Traversa Giuseppe, Bianchi Clara, Caffari Bruno, Da Cas Roberto, Panei Pietro
National Center of Epidemiology, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Roma, Italy.
Health Policy. 2004 Aug;69(2):151-7. doi: 10.1016/j.healthpol.2004.04.001.
In August 2001, cerivastatin was removed from European and USA markets because of a higher risk of rhabdomyolysis associated with its use in comparison with other statins. The objective of this study was to compare cholesterol-lowering drug use in Italy before and after the withdrawal of cerivastatin from the market, and to evaluate if the withdrawal influenced patients compliance and physicians prescribing habits. After August 2001, 48% of cerivastatin users discontinued any statin treatment. The major risk factor for discontinuation was a concomitant use of fibrate during the first 7 months of 2001 (OR = 2.3; 95% CI = -2.9). Comparing the discontinuation of statin therapy between 2001 and 2000 we can estimate that there was a 5% increase, corresponding to about 200,000 patients, who discontinued statin therapy during autumn 2001 because of cerivastatin emergency.
2001年8月，西立伐他汀因其与其他他汀类药物相比使用时横纹肌溶解风险更高而从欧洲和美国市场撤出。本研究的目的是比较西立伐他汀退市前后意大利的降胆固醇药物使用情况，并评估退市是否影响患者的依从性和医生的处方习惯。2001年8月之后，48%的西立伐他汀使用者停止了任何他汀类药物治疗。停药的主要风险因素是在2001年的前7个月同时使用贝特类药物（比值比=2.3；95%置信区间=-2.9）。比较2001年和2000年他汀类药物治疗的停药情况，我们可以估计，由于西立伐他汀事件，2001年秋季有5%的患者（约20万患者）停止了他汀类药物治疗。
